2013
DOI: 10.1002/prca.201200080
|View full text |Cite
|
Sign up to set email alerts
|

Quantitative mass spectrometry for colorectal cancer proteomics

Abstract: This review documents the uses of quantitative MS applied to colorectal cancer (CRC) proteomics for biomarker discovery and molecular pathway profiling. Investigators are adopting various labeling and label-free MS approaches to quantitate differential protein levels in cells, tumors, and plasma/serum. We comprehensively review recent uses of this technology to examine mouse models of CRC, CRC cell lines, their secretomes and subcellular fractions, CRC tumors, CRC patient plasma/serum, and stool samples. For b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(17 citation statements)
references
References 96 publications
(102 reference statements)
0
16
0
1
Order By: Relevance
“…Several previous proteomics studies have been carried out using specimens from patients with CRC (reviewed in [7]), however, none have examined the molecular differences in tumor tissues from patients with Stage III who achieved a good outcome and those who suffered distant recurrence, or assessed the differences separately in IIIB and IIIC subgroups. In this study, we used TMT-based MS to investigate distant recurrence-associated DEPs in patients with Stage IIIB and IIIC CRC.…”
Section: Discussionmentioning
confidence: 99%
“…Several previous proteomics studies have been carried out using specimens from patients with CRC (reviewed in [7]), however, none have examined the molecular differences in tumor tissues from patients with Stage III who achieved a good outcome and those who suffered distant recurrence, or assessed the differences separately in IIIB and IIIC subgroups. In this study, we used TMT-based MS to investigate distant recurrence-associated DEPs in patients with Stage IIIB and IIIC CRC.…”
Section: Discussionmentioning
confidence: 99%
“…This section describes the data sources and additional data processing steps applied in this study. An attempt was made to locate all currently available proteomic studies for clinical tissue on CRC including, among others, those listed in the "Tissue" and "Tissue subproteomes" sections of the review paper by de Wit et al (2013) and in Supporting Table 3 ("Clinical Samples") of the review paper by Martínez-Aguilar et al (2013). To make the comparisons more robust, only datasets with at least 30 proteins in each of the up-and down-regulated groups were considered; however, all datasets from a given 5/38 study were included if at least one of the datasets met this criterion.…”
Section: Data Sourcesmentioning
confidence: 99%
“…This section describes the data sources and additional data processing steps applied in this study. An attempt was made to locate all currently available proteomic studies for clinical tissue on CRC including, among others, those listed in the "Tissue" and "Tissue subproteomes" sections of the review paper by de Wit et al (2013) and in Supporting Table 3 ("Clinical Samples") of the review paper by Martínez-Aguilar et al (2013). To make the comparisons more robust, only datasets with at least 30 proteins in each of the up-and down-regulated groups were considered; however, all datasets from a given study were included if at least one of the datasets met this criterion.…”
Section: Data Sourcesmentioning
confidence: 99%